Fiche du document
Auteur
Date
7 novembre 2022
Type de document
Périmètre
Identifiant
- handle: 10670/1.bgb8kr
Source
Organisation
Sujets proches
Haemophilia Hematophilia Classic hemophilia Factor VIII deficiency Hemophilia A Hemorrhagic diathesisCiter ce document
lsgilbert, « First gene therapy to treat severe haemophilia A », ELSIBI, ID : 10670/1.bgb8kr
Métriques
Partage / Export
Résumé
EMA has recommended granting a conditional marketing authorisation in the European Union for Roctavian for the treatment of severe haemophilia A in adults who do not have factor VIII inhibitors and no antibodies to adeno-associated virus serotype 5. Read this news published by the European Medicines Agency on 24 June 2022.